Aclacinomycin A in the treatment of experimental proliferative vitreoretinopathy. Efficacy and toxicity in the rabbit eye.

PURPOSE Aclacinomycin A is an oligosaccharide anthracycline that, by contrast with daunomycin, lacks carcinogenicity. The authors evaluated the efficacy of aclacinomycin A in prevention of experimental proliferative vitreoretinopathy (PVR) and its toxicity on the rabbit retina. METHODS Dutch-belted rabbit were used to create a model for traction retinal detachment. Seven to 10 days after vitreous gas compression, 25,000 homologous fibroblasts were injected into the vitreous cavity. Subsequently, the eyes received either sham injections or doses of 6, 30, or 60 nmol of aclacinomycin A, respectively. The fundus findings were documented on days 7, 14, and 28 after the fibroblast injection. The toxicity studies were conducted according to the same protocol as was used for the efficacy evaluation but without the fibroblast injection. Simultaneous electroretinograms were recorded on days 0, 3, 7, and 14 from the right eyes that were injected with 30 or 60 nmol of aclacinomycin A and the left eyes that were sham injected. Morphologic studies were conducted on the eyes enucleated on days 3, 7, and 14 after drug exposure. RESULTS Intraocular administration of 30 nmol of aclacinomycin A on day 2 after fibroblast injection resulted in a detachment rate of 37.5% (controls, 100%; P < 0.01, by Fisher's exact test). Administration of 60 nmol of aclacinomycin A 3 days after fibroblast injection resulted in a detachment rate of 26.7% (controls, 100%; P < 0.0001). Six nanomoles of aclacinomycin A 3 days after fibroblast injection had no effect. No electroretinogram changes were present in eyes treated with 30 nmol of aclacinomycin A. Such recordings from eyes exposed to 60 nmol of aclacinomycin A demonstrated decreased a- and b-waves on day 3; these completely recovered by day 7. Morphologic studies of these eyes revealed no damage to the retina. CONCLUSIONS These results suggest that aclacinomycin A should be considered an alternative to daunomycin for treatment of human PVR because, in addition to its lack of carcinogenicity, it shows good efficacy and causes less retinal toxicity.

[1]  G. Samsa,et al.  The effect of combined daunorubicin and triamcinolone acetonide treatment on a refined experimental model of proliferative vitreoretinopathy. , 1992, Investigative ophthalmology & visual science.

[2]  P. Wiedemann,et al.  [Daunomycin and silicone oil in treatment of proliferative vitreoretinopathy]. , 1991, Fortschritte der Ophthalmologie : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

[3]  P. Wiedemann,et al.  Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy. , 1987, American journal of ophthalmology.

[4]  D. Hayes,et al.  Phase II study of aclarubicin in patients with lymphoma. , 1985, Cancer treatment reports.

[5]  J. Gockerman,et al.  Phase II evaluation of aclarubicin in advanced breast cancer: a Southeastern Cancer Study Group trial. , 1985, Cancer treatment reports.

[6]  R. Pazdur,et al.  Phase II evaluation of aclacinomycin‐A in patients with adenocarcinoma and large cell carcinoma of the lung , 1985, American journal of clinical oncology.

[7]  D. Decker,et al.  Phase II evaluation of aclacinomyin‐A (NSC‐208734) in adenocarcinoma of the kidney , 1984, American journal of clinical oncology.

[8]  U. Mohr,et al.  Tumorigenicity in vivo and induction of mutagenesis and DNA repair in vitro by aclacinomycin A and marcellomycin: structure-activity relationship and predictive value of short-term tests. , 1983, Cancer research.

[9]  F. Arcamone,et al.  Antibacterial activity of novel broad-spectrum "(5R)-penem" derivatives. , 1980, The Journal of antibiotics.

[10]  Kazumasa Yamada,et al.  ACLACINOMYCIN A, A NEW ANTI-LEUKÆMIC AGENT , 1979, The Lancet.

[11]  R. Machemer.  Pathogenesis and classification of massive periretinal proliferation. , 1978, The British journal of ophthalmology.

[12]  T. Sugimura,et al.  Mutagenicity of aclacinomycin A and daunomycin derivatives. , 1978, Cancer research.

[13]  T. Aaberg,et al.  Pigment epithelial proliferation in human retinal detachment with massive periretinal proliferation. , 1978, American journal of ophthalmology.

[14]  T. Aaberg,et al.  Glial cell proliferation in human retinal detachment with massive periretinal proliferation. , 1977, American journal of ophthalmology.

[15]  S. Sternberg,et al.  Tumorigenicity in vivo and induction of malignant transformation and mutagenesis in cell cultures by adriamycin and daunomycin. , 1976, Cancer research.

[16]  R. Machemer,et al.  Clinical-pathological correlation in massive periretinal proliferation. , 1975, American journal of ophthalmology.

[17]  T. Lawwill.  Practical rabbit electroretinography. , 1972, American journal of ophthalmology.

[18]  S. Sternberg,et al.  Renal tumors and other lesions in rats following a single intravenous injection of daunomycin. , 1972, Cancer research.

[19]  B. Spivey,et al.  Day-to-day variations in the ERG of humans and rabbits. , 1963, American journal of ophthalmology.

[20]  R. Michels,et al.  Surgical Treatment of PVR , 1988 .

[21]  J. Westendorf,et al.  Anthracycline Antitumor Antibiotics: Their Carcinogenicity and their Mutagenicity , 1982 .

[22]  T. Takeuchi,et al.  New anthracycline antibiotic aclacinomycin A: experimental studies and correlations with clinical trials. , 1981, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[23]  E. Bucciarelli.  Mammary Tumor Induction in Male and Female Sprague-Dawley Rats by Adriamycin and Daunomycin , 1981 .

[24]  T. Takeuchi,et al.  Current status of Japanese studies with the new anthracycline antibiotic aclacinomycin A. , 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[25]  S. Hirano,et al.  [Irritative effect of aclacinomycin A on the eye mucous membrane, skin and muscle (author's transl)]. , 1980, The Japanese journal of antibiotics.